Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Baxter International Inc. with ticker code (BAX) now have 15 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 110 and 88 calculating the mean target price we have 97.8. Now with the previous closing price of 86.1 this would imply there is a potential upside of 13.6%. The 50 day MA is 83.73 and the 200 day MA is 81.37. The company has a market cap of $43,415m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" symbol="BAX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $49,315m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

10 Dividend Growth Stocks For January 2022

09:00am, Sunday, 30'th Jan 2022
I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To pick candidates, I use different screens every month that focus on various as

New Strong Buy Stocks for January 18th

10:46am, Tuesday, 18'th Jan 2022
KBH, BAX, F, EGO, and AXS have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Best Income Stocks to Buy for January 18th

10:00am, Tuesday, 18'th Jan 2022
BAX, F, and WBS made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 18, 2022

Best Momentum Stocks to Buy for January 18th

10:00am, Tuesday, 18'th Jan 2022
BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022
We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.

New Strong Buy Stocks for January 17th

09:15am, Monday, 17'th Jan 2022
AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.
DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Baxter CEO: Omicron has created shortage of some medical supplies

07:50pm, Tuesday, 11'th Jan 2022 Seeking Alpha
Baxter International CEO José Almeida said the medical supply maker has seen some shortages lately as the surge of Omicron patients has led to a spike in demand for certain products.
BOSTON , Jan. 10, 2022 /PRNewswire/ -- Medically Home today announced a new, $110 million round of funding from strategic investors including Baxter International Inc., Global Medical Response (GMR) and Cardinal Health who will each have representation on the company''s Board. Cardinal Health, Mayo Clinic and Kaiser Permanente are providing additional capital on top of their previous investments, demonstrating confidence in the growing expansion of the model nationwide. Medically Home Announces a $110 Million Investment The Medically Home model unlocks patients'' homes as safe alternative sites to receive high and lower acuity care across the care continuum in the comfort and convenience of their homes. This capability is designed to increase health system capacity and resiliency, while meeting the needs and wants of patients, who often prefer to be cared for at home or in a homelike setting. More than 7,000 patients have been treated using the Medically Home platform and ecosystem, as delivered by health systems across the country and utilization is expanding rapidly.
Baxter International Inc. (BAX) shares closed today at 1.6% below its 52 week high of $88.91, giving the company a market cap of $43B. The stock is currently up 1.9% year-to-date, up 8.5% over the past 12 months, and up 103.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -279.4% The company's stock price performance over the past 12 months beats the peer average by 63.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Baxter International Inc. Shares Near 52-Week High - Market Mover

06:55pm, Saturday, 08'th Jan 2022 Kwhen Finance
Baxter International Inc. (BAX) shares closed today at 1.6% below its 52 week high of $88.91, giving the company a market cap of $43B. The stock is currently up 1.9% year-to-date, up 8.8% over the past 12 months, and up 103.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 0.1% higher than its 5-day moving average, 2.6% higher than its 20-day moving average, and 7.8% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -353.3% The company's stock price performance over the past 12 months beats the peer average by 46.8% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE